AAPL 169.3 -0.6047% MSFT 395.125 1.4885% GOOG 165.555 0.5558% GOOGL 163.795 0.6235% AMZN 178.86 2.2057% NVDA 830.03 -3.9339% META 439.1 2.0759% TSLA 179.995 -1.7923% TSM 134.94 -1.7475% LLY 776.75 -0.5569% V 267.29 -0.4914% AVGO 1242.86 -4.4152% JPM 191.86 0.0626% UNH 484.11 0.0848% NVO 129.21 0.7014% WMT 58.82 -0.893% LVMUY 164.02 -0.0792% XOM 116.06 -1.8686% LVMHF 822.33 -0.4443% MA 442.07 -2.0235%
Last update at 2024-05-01T20:10:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 21725.00M | 22776.00M | 16497.00M | 17328.00M | 17999.00M |
| Minority interest | - | - | - | - | - |
| Net income | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Selling general administrative | 24765.00M | 24659.00M | 22084.00M | 22178.00M | 22540.00M |
| Selling and marketing expenses | - | - | 22084.00M | 22178.00M | 22540.00M |
| Gross profit | 63854.00M | 63920.00M | 54157.00M | 54503.00M | 54490.00M |
| Reconciled depreciation | 6970.00M | 7390.00M | 7231.00M | 7009.00M | 6929.00M |
| Ebit | 17054.00M | 18309.00M | 13111.00M | 15117.00M | 15623.00M |
| Ebitda | 24024.00M | 25699.00M | 20342.00M | 22126.00M | 22552.00M |
| Depreciation and amortization | 6970.00M | 7390.00M | 7231.00M | 7009.00M | 6929.00M |
| Non operating income net other | -1381.00000M | -436.00000M | -2788.00000M | -2168.00000M | -794.00000M |
| Operating income | 23917.00M | 24417.00M | 19824.00M | 21009.00M | 20781.00M |
| Other operating expenses | 71240.00M | 69228.00M | 62670.00M | 61089.00M | 60406.00M |
| Interest expense | 276.00M | 183.00M | 201.00M | 318.00M | 1005.00M |
| Tax provision | 3784.00M | 1898.00M | 1783.00M | 2209.00M | 2702.00M |
| Interest income | 490.00M | 53.00M | 111.00M | 357.00M | 611.00M |
| Net interest income | 214.00M | -130.00000M | -90.00000M | 39.00M | -394.00000M |
| Extraordinary items | - | - | 300.00M | - | - |
| Non recurring | 1104.00M | 1152.00M | 428.00M | 1156.00M | 1377.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 3784.00M | 1898.00M | 1783.00M | 2209.00M | 2702.00M |
| Total revenue | 94943.00M | 93775.00M | 82584.00M | 82059.00M | 81581.00M |
| Total operating expenses | 40151.00M | 39373.00M | 34243.00M | 33533.00M | 33315.00M |
| Cost of revenue | 31089.00M | 29855.00M | 28427.00M | 27556.00M | 27091.00M |
| Total other income expense net | -2192.00000M | -1641.00000M | -3327.00000M | -3681.00000M | -2782.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Net income applicable to common shares | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 187378.00M | 182018.00M | 174894.00M | 157728.00M | 152954.00M |
| Intangible assets | 48325.00M | 46392.00M | 53402.00M | 47643.00M | 47611.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 3132.00M | 3701.00M | 3132.00M | 2486.00M | 3649.00M |
| Total liab | 110574.00M | 107995.00M | 111616.00M | 98257.00M | 93202.00M |
| Total stockholder equity | 76804.00M | 74023.00M | 63278.00M | 59471.00M | 59752.00M |
| Deferred long term liab | 6374.00M | 7487.00M | 7214.00M | 5958.00M | 7506.00M |
| Other current liab | 31328.00M | 30405.00M | 30357.00M | 26218.00M | 13257.00M |
| Common stock | 3120.00M | 3120.00M | 3120.00M | 3120.00M | 3120.00M |
| Capital stock | 3120.00M | 3120.00M | 3120.00M | 3120.00M | 3120.00M |
| Retained earnings | 128345.00M | 123060.00M | 113890.00M | 110659.00M | 106216.00M |
| Other liab | 26584.00M | 31784.00M | 35388.00M | 35083.00M | 34285.00M |
| Good will | 45231.00M | 35246.00M | 36393.00M | 33639.00M | 30453.00M |
| Other assets | 17049.00M | 17155.00M | 3896.00M | 11408.00M | 11305.00M |
| Cash | 14127.00M | 14487.00M | 13985.00M | 17305.00M | 18107.00M |
| Cash and equivalents | 5368.00M | 1901.00M | 2102.00M | 2864.00M | 3397.00M |
| Total current liabilities | 55802.00M | 45226.00M | 42493.00M | 35964.00M | 31230.00M |
| Current deferred revenue | - | - | - | 7819.00M | 7640.00M |
| Net debt | 25532.00M | 19264.00M | 21281.00M | 10391.00M | 12373.00M |
| Short term debt | 12771.00M | 3766.00M | 2631.00M | 1202.00M | 2796.00M |
| Short long term debt | 12771.00M | 3766.00M | 2631.00M | 1202.00M | 2796.00M |
| Short long term debt total | 39659.00M | 33751.00M | 35266.00M | 27696.00M | 30480.00M |
| Other stockholder equity | -41694.00000M | -39099.00000M | -38490.00000M | -38417.00000M | -34362.00000M |
| Property plant equipment | 19803.00M | 18962.00M | 18766.00M | 17658.00M | 17035.00M |
| Total current assets | 55294.00M | 60979.00M | 51237.00M | 45274.00M | 46033.00M |
| Long term investments | - | - | - | 1149.00M | 517.00M |
| Net tangible assets | -16752.00000M | -13073.00000M | -26517.00000M | -21811.00000M | -18312.00000M |
| Short term investments | 9392.00M | 17121.00M | 11200.00M | 1982.00M | 1580.00M |
| Net receivables | 16160.00M | 15283.00M | 13576.00M | 14481.00M | 14098.00M |
| Long term debt | 26888.00M | 29985.00M | 32635.00M | 26494.00M | 27684.00M |
| Inventory | 12483.00M | 10387.00M | 9344.00M | 9020.00M | 8599.00M |
| Accounts payable | 11703.00M | 11055.00M | 9505.00M | 8544.00M | 7537.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -12967.00000M | -13058.00000M | -15242.00000M | -15891.00000M | -15222.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 3120.00M | 3120.00M | 3120.00M | 3120.00M | 3120.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 128345.00M | 123060.00M | 113890.00M | 110659.00M | 106216.00M |
| Treasury stock | -41694.00000M | -39099.00000M | -38490.00000M | -38417.00000M | -34362.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9602.00M | 10216.00M | 6562.00M | 5695.00M | -7909.00000M |
| Deferred long term asset charges | - | - | - | 7819.00M | 7640.00M |
| Non current assets total | 132084.00M | 121039.00M | 123657.00M | 112454.00M | 106921.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 26888.00M | 29985.00M | 32635.00M | 26494.00M | 27684.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 9225.00M | -5388.00000M | -8952.00000M | -533.00000M | -1337.00000M |
| Change to liabilities | -881.00000M | 1376.00M | 5885.00M | 5485.00M | 2107.00M |
| Total cashflows from investing activities | -12371.00000M | -8683.00000M | -20825.00000M | -6194.00000M | -3167.00000M |
| Net borrowings | 7452.00M | -990.00000M | 7095.00M | -2881.00000M | -3949.00000M |
| Total cash from financing activities | -8871.00000M | -14047.00000M | -6120.00000M | -18015.00000M | -18510.00000M |
| Change to operating activities | -1292.00000M | -3025.00000M | -2960.00000M | 371.00M | -2119.00000M |
| Net income | 17941.00M | 20878.00M | 14714.00M | 15119.00M | 15297.00M |
| Change in cash | -360.00000M | 502.00M | -3320.00000M | -802.00000M | 283.00M |
| Begin period cash flow | 14487.00M | 13985.00M | 17305.00M | 18107.00M | 17824.00M |
| End period cash flow | 14127.00M | 14487.00M | 13985.00M | 17305.00M | 18107.00M |
| Total cash from operating activities | 21194.00M | 23410.00M | 23536.00M | 23416.00M | 22201.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 6970.00M | 7390.00M | 7231.00M | 7009.00M | 6929.00M |
| Other cashflows from investing activities | -17587.00000M | 357.00M | -8526.00000M | -2163.00000M | 1840.00M |
| Dividends paid | -11682.00000M | -11032.00000M | -10481.00000M | -9917.00000M | 9494.00M |
| Change to inventory | -2527.00000M | -1248.00000M | -265.00000M | -277.00000M | -644.00000M |
| Change to account receivables | -1290.00000M | -2402.00000M | 774.00M | -289.00000M | -1185.00000M |
| Sale purchase of stock | -6035.00000M | -3456.00000M | -3221.00000M | -6746.00000M | -5868.00000M |
| Other cashflows from financing activities | 17530.00M | 395.00M | -627.00000M | 575.00M | -148.00000M |
| Change to netincome | 294.00M | -620.00000M | -1099.00000M | -2577.00000M | -28.00000M |
| Capital expenditures | 4009.00M | 3652.00M | 3347.00M | 3498.00M | 3670.00M |
| Change receivables | -1290.00000M | -2402.00000M | 774.00M | -289.00000M | -1185.00000M |
| Cash flows other operating | 687.00M | -1964.00000M | -3704.00000M | -1054.00000M | -275.00000M |
| Exchange rate changes | - | - | - | - | -241.00000M |
| Cash and cash equivalents changes | -48.00000M | 680.00M | -3409.00000M | -793.00000M | 283.00M |
| Change in working capital | -4011.00000M | -4238.00000M | 2690.00M | 3865.00M | 3.00M |
| Stock based compensation | 1138.00M | 1135.00M | 1005.00M | 977.00M | 978.00M |
| Other non cash items | 819.00M | 324.00M | -963.00000M | -1078.00000M | 10.00M |
| Free cash flow | 17185.00M | 19758.00M | 20189.00M | 19918.00M | 18531.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson |
6.59 4.56% | 151.18 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| LLY Eli Lilly and Company |
-4.35 0.56% | 776.75 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| ABBV AbbVie Inc |
-0.92 0.57% | 161.72 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| MRK Merck & Company Inc |
-0.4 0.31% | 128.82 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| RHHVF Roche Holding AG Participation |
-2.8 1.17% | 236.00 | 17.21 | 12.08 | 3.61 | 7.37 | 4.15 | 13.04 |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
| Name | Title | Year Born |
|---|---|---|
| Mr. Alex Gorsky | Exec. Chairman | 1960 |
| Mr. Joaquin Duato | CEO & Director | 1963 |
| Mr. Joseph J. Wolk CPA | Exec. VP & CFO | 1967 |
| Ms. Jennifer L. Taubert | Exec. VP & Worldwide Chairman of Pharmaceuticals | 1964 |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | 1972 |
| Mr. James Swanson | Exec. VP & Chief Information Officer | NA |
| Ms. Jessica Moore | VP of Investor Relations | NA |
| Mr. Dirk Brinckman | Chief Compliance Officer | NA |
| Ms. Elizabeth Forminard | Exec. VP & Gen. Counsel | NA |
| Dr. Peter M. Fasolo Ph.D. | Exec. VP & Chief HR Officer | 1963 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...